BioNTech SE

BioNTech SE

Yahoo Finance • 17 hours ago

Cathie Wood Loads Up on SpaceX, Meta, Eli Lilly and Circle Group

This article first appeared on GuruFocus. Cathie Wood's ARK Invest increased positions in several technology, healthcare and digital asset companies during the week ended July 10, while reducing holdings in select semiconductor and genomi... Full story

Yahoo Finance • 22 hours ago

Cathie Wood reshuffles portfolio ahead of Q2, buys SpaceX, Eli Lilly, Meta; pares AMD, Roku

Cathie Wood's ARK Invest's largest purchase during the last week by value was Elon Musk's Space Exploration Technologies (SPCX [https://seekingalpha.com/symbol/SPCX]), adding a combined 349K shares across ARKK, ARKQ, ARKW and ARKX for ~$52... Full story

Yahoo Finance • 8 days ago

WHO begins experimental Ebola trial as Congo outbreak claims 500+ lives

Patients infected with the Bundibugyo strain of Ebola have begun receiving experimental treatments in a World Health Organization-sponsored clinical trial aimed at improving care for the rare viral disease, which has claimed more than 500... Full story

Yahoo Finance • 10 days ago

BioNTech has reportedly contacted buyers over plans to exit German sites

[BioNTech And Pfizer To Begin Clinical Trial For Covid-19 Vaccine] Thomas Lohnes/Getty Images News COVID-19 vaccine maker BioNTech (BNTX [https://seekingalpha.com/symbol/BNTX]) has conducted confidential discussions with prospective bidde... Full story

Yahoo Finance • 13 days ago

Bristol Myers Squibb vs. Johnson & Johnson: Which Healthcare Stock Is a Better Buy in 2026?

Choosing between Bristol Myers Squibb (NYSE:BMY) and Johnson & Johnson (NYSE:JNJ) means deciding whether you prefer a pure-play pharmaceutical company trading at a deep discount or a diversified giant with higher growth. While both operat... Full story

Yahoo Finance • 13 days ago

mRNA Cancer Vaccine Market to Surpass $1.20 Billion in 2026 as Personalized Oncology Immunotherapies Advance, New Report Finds

Dublin, July 01, 2026 (GLOBE NEWSWIRE) -- The "mRNA Cancer Vaccine Market Report 2026-2036" has been added to ResearchAndMarkets.com's offering. This comprehensive report provides an in-depth analysis of the global mRNA cancer vaccine... Full story

Yahoo Finance • 17 days ago

2 Biotech Stocks Worth Buying Before Their Potential Buyouts

Dealmaking is back with a vengeance in the pharmaceutical sector this year. According to a report by PwC, there were more than $65 billion in pharma and life sciences mergers & acquisitions in the first quarter, the best quarter for the se... Full story

Yahoo Finance • 19 days ago

The New War on Cancer: Four Public Companies Helping Lead a Medical Revolution

DENVER, June 25, 2026 (GLOBE NEWSWIRE) -- (247marketnews.com) – Cancer treatment is undergoing one of the most significant transformations in modern medical history. For decades, physicians relied primarily on surgery, radiation, and ch... Full story

Yahoo Finance • 27 days ago

US Equity Markets End Lower After Government Bond Yields Rise, Fed's Policy Statement

US equity indexes were lower on Wednesday as government bond yields rose and the Federal Reserve ann PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story

Yahoo Finance • 27 days ago

Moderna eyes German production sites amid BioNTech plant closures - report

[Modern, Inc.] hapabapa U.S. vaccine maker Moderna (MRNA [https://seekingalpha.com/symbol/MRNA]) is exploring investments in manufacturing facilities in Germany and is particularly interested in acquiring sites that rival BioNTech (BNTX [... Full story

Yahoo Finance • last month

BioNTech (BNTX) and Bristol Myers Share New Results From ROSETTA Lung-02 Study

BioNTech SE (NASDAQ:BNTX) is one of the best healthcare stocks to buy with highest upside potential. BioNTech SE (NASDAQ:BNTX) and Bristol Myers Squibb Company announced on May 30 interim Phase 2 data from the global Phase 2/3 ROSETTA Lung... Full story

Yahoo Finance • last month

European Equities Traded in the US as American Depositary Receipts Decline in Monday Trading

European equities traded in the US as American depositary receipts started the trading week lower la PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story

Yahoo Finance • last month

Global Data for BioNTech and Bristol Myers Squibb’s PD-L1xVEGF-A Bispecific Pumitamig Shows Encouraging Efficacy in Patients with Non-Small Cell Lung Cancer in ROSETTA Lung-02 Trial

First investigational PD-(L)1xVEGF bispecific immunomodulator to present global data showing encouraging efficacy in combination with chemotherapy in first-line non-small cell lung cancer across PD-L1 expression levels and subtypes, highli... Full story

Yahoo Finance • last month

Globale Daten der ROSETTA Lung-02-Studie: Ermutigende Wirksamkeit für BioNTechs und Bristol Myers Squibbs bispezifischen PD-L1xVEGF-A-Immunmodulator-Kandidat Pumitamig bei nicht-kleinzelligem Lungenkrebs

Erster bispezifischer PD-(L)1xVEGF-Immunmodulator-Kandidat, zu dem globale Daten mit ermutigender Wirksamkeit in Kombination mit Chemotherapie in der Erstlinienbehandlung von nicht-kleinzelligem Lungenkrebs über verschiedene PD-L1-Expressi... Full story

Yahoo Finance • 2 months ago

European Equities Traded in the US as American Depositary Receipts Rise in Friday Trading; Flat for Week

European equities traded in the US as American depositary receipts were rising late Friday morning, PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium... Full story

Yahoo Finance • 2 months ago

European Equities Traded in the US as American Depositary Receipts Decline in Wednesday Trading

European equities traded in the US as American depositary receipts were tracking lower late Wednesda PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story

Yahoo Finance • 2 months ago

This Biotech Stock Is Stuck in the Red. Its Cancer Portfolio Is About to Change the Narrative.

BioNTech’s future rests entirely on the success of its pipeline, now that its pandemic-era glory days are firmly in the rearview mirror. Wall Street is betting the company’s next act in oncology will be worth the wait. UBS analyst David Da... Full story

Yahoo Finance • 2 months ago

BioNTech to Showcase Progress Across Late-Stage Oncology Pipeline at the 2026 ASCO Annual Meeting

Pumitamig data from the ongoing Phase 2/3 ROSETTA Lung-02 trial in first-line non-small cell lung cancer mark the third global data set to consistently show encouraging anti-tumor activity for pumitamig in combination with chemotherapyGoti... Full story

Yahoo Finance • 2 months ago

BioNTech präsentiert auf der ASCO-Jahrestagung 2026 Fortschritte aus Pipelineprogrammen in der späten klinischen Entwicklung

Daten zu Pumitamig aus der laufenden Phase-2/3-Studie ROSETTA Lung-02 bei nicht-kleinzelligem Lungenkrebs in der Erstlinienbehandlung bilden den dritten globalen Studien-Datensatz, der eine ermutigende Anti-Tumor-Aktivität von Pumitamig in... Full story

Yahoo Finance • 2 months ago

JPMorgan sees biotech sector at inflection point, resumes coverage on 14 Firms

Investing.com -- JPMorgan has reinstated ratings and price targets on 14 large-cap biotechnology companies, describing the sector as being at a critical “inflection point” as pipeline successes increasingly translate into profitable commer... Full story